This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2011 Fourth Quarter And Full Year Results

Cash flows from operations for the fourth quarter and full year 2011 were $31 million and $90 million, respectively, compared to $5 million and $77 million, respectively, for the comparable 2010 periods. Cash flows from operations for the fourth quarter of 2010 included the payment of the Electrochem litigation settlement of $25 million ($16.3 million net of tax). During 2011, the Company repaid $40 million of its long-term debt and borrowed an additional $45 million under its revolving credit facility in order to partially fund the Micro Power acquisition.

CFO Comments

“Overall, we are very pleased with our 2011 results,” commented Thomas J. Mazza, Senior Vice President & CFO. “Despite the challenges that our markets and the macroeconomic environment presented, we were able to exceed our revenue and adjusted earnings per share targets set at the beginning of the year. Our efficient operations continue to generate significant cash flow which allows us to execute on our strategic initiatives. These strategic initiatives will continue to drive our growth in the future.”
Product Line Sales              
The following table summarizes the Company’s sales by major product lines (dollars in thousands):
2011 2010 % 2011 % 2011 2010 %
Product Line 4th Qtr. 4th Qtr. Chg. 3rd Qtr. Chg. Year Year Chg.
Greatbatch Medical
CRM/Neuromodulation $ 77,198 $ 78,382 -2% $ 70,731 9% $ 303,690 $ 303,521 0%
Vascular Access 12,459 9,768 28% 11,396 9% 45,098 38,000 19%
Orthopaedic   31,635   30,773 3%   31,131 2%   140,277   118,748 18%
Total 121,292 118,923 2% 113,258 7% 489,065 460,269 6%
Electrochem   20,454   14,188 44%   18,460 11%   79,757   73,156 9%
Total sales $ 141,746 $ 133,111 6% $ 131,718 8% $ 568,822 $ 533,425 7%

Greatbatch Medical

In comparison to the prior year, CRM and Neuromodulation sales for the fourth quarter of 2011 decreased 2% but were consistent for the full year period. During the first half of 2011, CRM revenue included the benefit of customer inventory builds and product launches, which did not recur in the second half of 2011. Additionally, CRM and Neuromodulation sales continue to be impacted by pricing pressures and a slowdown in the underlying market. As a result of these headwinds, we expect CRM and Neuromodulation revenue for 2012 to be lower in the first half of 2012 but begin to rebound in the second half of the year as the CRM market stabilizes.

5 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs